- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00094887
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
This study will examine whether nitric oxide (NO) gas can reduce the time it takes for pain to go away in patients who are in sickle cell crisis. NO is important in regulating blood vessel dilation, and consequently, blood flow. The gas is continuously produced by cells that line the blood vessels. It is also transported from the lungs by hemoglobin in red blood cells.
Patients 10 years of age or older with sickle cell disease (known SS, S-beta-thalassemia or other blood problems causing sickle cell disease) may be eligible for this study. Patients whose disease is due to hemoglobin (Hgb) SC are excluded. Candidates are screened with blood tests and a chest x-ray to look at the lungs and heart.
Participants are admitted to the hospital in a pain crisis. They are evaluated and then randomly assigned to receive one of two treatments: 1) standard treatment plus NO, or 2) standard treatment plus placebo. The placebo used in this study is nitrogen, a gas that makes up most of the air we breathe and is not known to help in sickle cell disease.
For the first 8 hours of the study, patients receive placebo or NO through a facemask. The mask may be taken off for 5 minutes every hour and for not more than 20 minutes to eat a meal. After the first 8 hours, the gas is delivered through a nasal cannula (small plastic tubing that rests under the nose) that may be taken off only while showering or using the restroom. Patients are questioned about the severity of their pain when they start the study and then every few hours while they are in the hospital. Their vital signs (temperature, breathing rate, and blood pressure) and medicines are checked. Patients will breathe the gas for a maximum of 3 days, but will stay hospitalized until the patient feels well enough to go home. Patients are followed up about 1 month after starting the study by a return visit to the hospital or by a phone call.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
California
-
Oakland, California, United States, 94609-1809
- Children's Hospital Oakland
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Colorado Sickle Cell Treatement and Research Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20060
- Howard University Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02115
- Childrens Hospital, Boston
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-2602
- Case Western Reserve University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19134
- St. Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, United States, 15213-2583
- Childrens Hospital, Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each subject must meet all of the following inclusion criteria during the screening process in order to participate in the study:
- Patient must have a diagnosis of SCD (known SS, S-Beta-thalassemia or other hemoglobinopathies causing sickle cell disease). Patients with disease due to Hgb SC are not permitted.
- Must present to the ED/EC or other appropriate unit in VOC.
- Greater than or equal to 10 years old.
- Written informed consent/assent has been obtained.
Exclusion Criteria:
Subjects meeting any of the following criteria during baseline evaluation will be excluded from entry into the study:
- Exposure to therapeutic nitric oxide within the past 12 hours.
- Patient has received sildenafil or other phosphodiesterase 5 inhibitors, therapeutic L-arginine, nitroprusside or nitroglycerine within the past 12 hours.
- Patient has received previous ED/EC or other appropriate unit treatment for a vaso-occlusive crisis less than 48 hours or hospitalization less than 14 days ago (patients transferred directly from another ED or clinic may be enrolled).
- Patient has visited the ED/EC or other appropriate unit greater than 10 times in the past year having a vaso-occlusive crisis.
- Patients presenting with clinically diagnosed bacterial infection (e.g., osteomyelitis, pneumonia, sepsis or meningitis).
- Patients who are currently enrolled in any other investigational drug study except for hydroxyurea studies.
- Pregnant women (urine HCG + )/ nursing mothers.
- Patients who have received an exchange transfusion (not simple transfusion) in the last 30 days or are on a chronic simple or exchange transfusion program.
- Suspected splenic sequestration.
- Acute chest syndrome or pneumonia: Abnormal new pulmonary infiltrate (alveolar infiltration and not atelectasis) and one or more pulmonary signs and/or symptoms (fever, rales, wheezing, cough, shortness of breath, retractions).
- Previous participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhaled Nitric Oxide
Participants receive Inhaled nitric oxide (INO)
|
Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask.
The dose will then be reduced to 40 ppm for 4 hours.
After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
Other Names:
|
Placebo Comparator: Placebo
Participants receive Nitrogen gas
|
Nitrogen gas will be delivered in the same manor as the experimental drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Vaso-occlusive Pain Crisis (VOC) Resolution
Time Frame: within 30 days
|
VOC resolution was defined by all of the following conditions:
|
within 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of Hospitalization
Time Frame: within 40 days
|
Length of hospitalization is defined as the length of time from admission to discharge order
|
within 40 days
|
Number of Participants Discharged to Home Within the First 24 Hours
Time Frame: within 24 hours
|
within 24 hours
|
|
Total Dose of Opioids Received
Time Frame: within 8 hours and within 40 days
|
The total dose (mg) of opioid medications received during the trial
|
within 8 hours and within 40 days
|
Number of Participants With Acute Chest Syndrome/Pneumonia Requiring Blood Transfusion
Time Frame: within 40 days
|
Number of participants who required a blood transfusion before discharge because of acute chest syndrome/pneumonia
|
within 40 days
|
Number of Participants Readmitted to Hospital Within 30 Days After Discharge
Time Frame: during first 24 hours and during 30 day follow-up
|
The number of participants readmitted to the hospital for any reason within 30 days after discharge
|
during first 24 hours and during 30 day follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: James Baldassarre, MD, Mallinckrodt
Publications and helpful links
General Publications
- Sanders DY, Severance HW, Pollack CV Jr. Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. South Med J. 1992 Aug;85(8):808-11. doi: 10.1097/00007611-199208000-00005.
- Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF; DeNOVO Investigators. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011 Mar 2;305(9):893-902. doi: 10.1001/jama.2011.235.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Nitric Oxide
Other Study ID Numbers
- INOT 36
- 05-H-0019 (Registry Identifier: NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia, Sickle Cell
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationSickle Cell Anemia | Sickle Beta Thalassemia | Sickle Cell Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Pain | Hbss | Hbsc | Sickle Cell Syndrome VariantUnited States
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRecruitingSickle Cell Disease | Sickle Cell Anemia in ChildrenAngola
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
National Institute of Diabetes and Digestive and...RecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell TraitUnited States
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, Makkah; Benisuef university...CompletedSickle Cell Disease | Vaso-occlusive Crisis | Sickle Cell Anemia in ChildrenEgypt, Saudi Arabia
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
Global Health Uganda LTDEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSickle Cell Anemia in ChildrenUganda
Clinical Trials on Nitric Oxide
-
Beyond Air Inc.Recruiting
-
Tomsk National Research Medical Center of the Russian...Siberian State Medical UniversityCompletedCoronavirus Infection | Pneumonia, Viral | HypoxemiaRussian Federation
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
BellerophonCompletedChronic Obstructive Pulmonary Disease | Idiopathic Pulmonary Fibrosis | Pulmonary HypertensionBelgium
-
MallinckrodtCompletedIdiopathic Pulmonary Arterial Hypertension | CardiomyopathyUnited Kingdom, United States, France, Spain, Netherlands
-
William Beaumont HospitalsTerminatedClostridium Difficile ColitisUnited States
-
National Institute of Neurological Disorders and...CompletedHealthy | Fabry Disease | Cerebrovascular AccidentUnited States
-
Origin Inc.UnknownDiabetic Foot UlcerUnited States
-
Massachusetts General HospitalRecruiting
-
National Institute of General Medical Sciences...Completed